Medpace Holdings, Inc. (NASDAQ:MEDP) – Analysts at KeyCorp issued their Q1 2018 earnings estimates for Medpace Holdings in a research note issued to investors on Monday. KeyCorp analyst D. Hooker forecasts that the company will post earnings of $0.40 per share for the quarter. KeyCorp currently has a “Hold” rating on the stock. KeyCorp also issued estimates for Medpace Holdings’ Q2 2018 earnings at $0.42 EPS, Q3 2018 earnings at $0.44 EPS, Q4 2018 earnings at $0.46 EPS and FY2019 earnings at $1.94 EPS.
MEDP has been the topic of a number of other reports. William Blair lowered shares of Medpace Holdings from an “outperform” rating to a “market perform” rating in a research note on Wednesday. They noted that the move was a valuation call. Raymond James Financial, Inc. started coverage on shares of Medpace Holdings in a research note on Friday, September 29th. They issued a “market perform” rating on the stock. Robert W. Baird lifted their price objective on shares of Medpace Holdings from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday. Jefferies Group LLC restated a “hold” rating and issued a $31.00 price objective (up from $30.00) on shares of Medpace Holdings in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research upgraded shares of Medpace Holdings from a “sell” rating to a “hold” rating and set a $33.00 price objective on the stock in a research note on Thursday, August 3rd. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $34.80.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/11/01/analysts-issue-forecasts-for-medpace-holdings-inc-s-q1-2018-earnings-medp.html.
Medpace Holdings (NASDAQ:MEDP) traded down 3.87% during midday trading on Wednesday, reaching $36.02. 115,666 shares of the company’s stock traded hands. Medpace Holdings has a 1-year low of $21.76 and a 1-year high of $39.64. The company has a market capitalization of $1.42 billion, a PE ratio of 63.42 and a beta of -0.86. The firm’s 50 day moving average price is $32.96 and its 200-day moving average price is $30.01.
Medpace Holdings (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, October 30th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The firm had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace Holdings had a net margin of 6.44% and a return on equity of 9.74%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.40 earnings per share.
Several large investors have recently modified their holdings of MEDP. Bernzott Capital Advisors boosted its holdings in shares of Medpace Holdings by 141.4% in the second quarter. Bernzott Capital Advisors now owns 593,840 shares of the company’s stock valued at $17,221,000 after acquiring an additional 347,804 shares in the last quarter. Granite Investment Partners LLC purchased a new stake in shares of Medpace Holdings in the second quarter valued at about $8,118,000. Redmile Group LLC purchased a new stake in shares of Medpace Holdings in the second quarter valued at about $6,526,000. Ameriprise Financial Inc. purchased a new stake in shares of Medpace Holdings in the second quarter valued at about $6,402,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Medpace Holdings by 23.3% in the second quarter. Vanguard Group Inc. now owns 1,014,439 shares of the company’s stock valued at $29,419,000 after acquiring an additional 191,597 shares in the last quarter. 16.32% of the stock is currently owned by institutional investors and hedge funds.
In other Medpace Holdings news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of Medpace Holdings stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $30.27, for a total value of $60,540,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 25.80% of the company’s stock.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.